Literature DB >> 3386818

Prevalence and natural history of progressive supranuclear palsy.

L I Golbe1, P H Davis, B S Schoenberg, R C Duvoisin.   

Abstract

We surveyed neurologists and chronic care facilities in and near two New Jersey counties with a combined population of 799,022, regarding cases of progressive supranuclear palsy. All suspected cases were examined personally, using rigid criteria. The prevalence ratio was 1.39/100,000. A total of 50 New Jersey cases yielded median intervals to onset of requiring gait assistance, 3.1 years; visual symptoms, 3.9 years; dysarthria, 3.4 years; dysphagia, 4.4 years; requiring wheelchair, 8.2 years; and death, 9.7 years.

Entities:  

Mesh：

Year:  1988        PMID： 3386818     DOI： 10.1212/wnl.38.7.1031

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  49 in total

Review 1.  Progressive supranuclear palsy.

Authors:  H U Rehman
Journal:  Postgrad Med J       Date:  2000-06       Impact factor: 2.401

Review 2.  Neuropsychiatry of the basal ganglia.

Authors:  H A Ring; J Serra-Mestres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

Review 3.  Multiple system atrophy--the nature of the beast.

Authors:  N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 4.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 5.  Parkinsonism--recognition and differential diagnosis.

Authors:  N Quinn
Journal:  BMJ       Date:  1995-02-18

Review 6.  Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches.

Authors:  Nikolaus R McFarland; Christopher W Hess
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 7.  Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report.

Authors:  Deborah A Hall; Maria João Forjaz; Lawrence I Golbe; Irene Litvan; Christine Ann M Payan; Christopher G Goetz; Albert F G Leentjens; Pablo Martinez-Martin; Anne Pavy-Le Traon; Cristina Sampaio; Bart Post; Glenn Stebbins; Daniel Weintraub; Anette Schrag
Journal:  Mov Disord Clin Pract       Date:  2015-05-22

8.  Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria.

Authors:  S J Collins; J E Ahlskog; J E Parisi; D M Maraganore
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

9.  Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.

Authors:  I Litvan; C A Mangone; A McKee; M Verny; A Parsa; K Jellinger; L D'Olhaberriague; K R Chaudhuri; R K Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 10.  The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).

Authors:  Adam L Boxer; Michael Gold; Edward Huey; William T Hu; Howard Rosen; Joel Kramer; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; George Jackson; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven S Khachaturian; Margaret Sutherland; Susan Abushakra; Joseph Lewcock; Robert Farese; Robert O Kenet; Frank Laferla; Steve Perrin; Steve Whitaker; Lawrence Honig; Marsel M Mesulam; Brad Boeve; Murray Grossman; Bruce L Miller; Jeffrey L Cummings
Journal:  Alzheimers Dement       Date:  2012-10-10       Impact factor: 21.566
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.